Published in J Med Genet on November 01, 1996
Pancreatitis and pancreatic cancer in two large pooled case-control studies. Cancer Causes Control (2009) 1.32
Radiofrequency ablation combined with palliative surgery may prolong survival of patients with advanced cancer of the pancreas. Langenbecks Arch Surg (2006) 1.26
Serum cadmium levels in pancreatic cancer patients from the East Nile Delta region of Egypt. Environ Health Perspect (2006) 1.11
Novel INTeraction of MUC4 and galectin: potential pathobiological implications for metastasis in lethal pancreatic cancer. Clin Cancer Res (2010) 1.03
Polymorphisms in GSTM1, GSTT1 and CYP1A1 and risk of pancreatic adenocarcinoma. Br J Cancer (2000) 0.83
Development of a cytokine-modified allogeneic whole cell pancreatic cancer vaccine. Methods Mol Biol (2013) 0.80
Detection of oncogenes in chronic pancreatitis. HPB (Oxford) (2003) 0.80
Bilateral burkitt lymphoma of the ovaries: a report of a case in a child with williams syndrome. Case Rep Med (2011) 0.79
Genetic implications of double primary cancers of the colorectum and endometrium. J Med Genet (1998) 0.79
Pancreatic cancer: any prospects for prevention? Postgrad Med J (1999) 0.76
A genetic model for colorectal tumorigenesis. Cell (1990) 44.37
ras oncogenes in human cancer: a review. Cancer Res (1989) 22.03
A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science (1995) 15.20
A cell cycle regulator potentially involved in genesis of many tumor types. Science (1994) 13.00
DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science (1996) 11.13
Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell (1988) 10.29
5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med (1995) 9.10
Identification of a chromosome 18q gene that is altered in colorectal cancers. Science (1990) 8.32
A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell (1991) 7.29
The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet (1996) 6.43
A cancer family syndrome in twenty-four kindreds. Cancer Res (1988) 6.39
Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst (1994) 6.27
Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer (1993) 6.24
Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (1994) 6.06
Germline p16 mutations in familial melanoma. Nat Genet (1994) 5.59
Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer (1988) 5.24
Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet (1994) 4.63
Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med (1987) 4.55
A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes. Nat Genet (1996) 4.38
Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med (1995) 4.10
Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer (1993) 3.86
Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med (1987) 3.86
Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA (1995) 3.83
Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet (1995) 3.76
K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol (1993) 3.56
Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet (1996) 3.56
Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet (1994) 3.38
Allelotype of pancreatic adenocarcinoma using xenograft enrichment. Cancer Res (1995) 3.33
KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res (1988) 3.31
The ras gene family and human carcinogenesis. Mutat Res (1988) 3.20
Participation in normal immune responses of a metastasis-inducing splice variant of CD44. Science (1992) 3.05
Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer (1995) 2.85
Morphoregulatory molecules. Biochemistry (1988) 2.75
Late mortality after surgery for peptic ulcer. N Engl J Med (1982) 2.73
Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci U S A (1994) 2.64
Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med (1995) 2.34
Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res (1994) 2.26
A prospective study of pancreatic cancer in the elderly. Int J Cancer (1994) 2.25
Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res (1993) 2.22
Pancreatitis is a risk factor for pancreatic cancer. Gastroenterology (1995) 2.11
Allelotype of pancreatic adenocarcinoma. Cancer Res (1994) 2.11
Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nat Genet (1995) 2.11
Cancer and the Peutz-Jeghers syndrome. Gut (1989) 2.09
Pancreas cancer and smoking, beverage consumption, and past medical history. J Natl Cancer Inst (1986) 1.95
K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res (1994) 1.86
Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut (1993) 1.85
High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer (1989) 1.79
Comparative genomic analysis of tumors: detection of DNA losses and amplification. Proc Natl Acad Sci U S A (1995) 1.75
Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res (1996) 1.75
The hereditary pancreatitis gene maps to long arm of chromosome 7. Hum Mol Genet (1996) 1.71
Mutations associated with familial melanoma impair p16INK4 function. Nat Genet (1995) 1.69
Founding BRCA1 mutations in hereditary breast and ovarian cancer in southern Sweden. Am J Hum Genet (1996) 1.69
Frequent somatic mutations of the APC gene in human pancreatic cancer. Cancer Res (1992) 1.55
Cancer in homozygotes and heterozygotes of ataxia-telangiectasia and xeroderma pigmentosum in Britain. Cancer Res (1988) 1.54
Life-style risk factors for pancreatic cancer in Louisiana: a case-control study. Am J Epidemiol (1988) 1.54
Heredity and malignant melanoma: implications for early cancer detection. Can Med Assoc J (1968) 1.50
The impact of family history on ovarian cancer risk. The Utah Population Database. Arch Intern Med (1995) 1.50
Williams syndrome: autosomal dominant inheritance. Am J Med Genet (1993) 1.45
Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region. Proc Natl Acad Sci U S A (1995) 1.44
Linkage analysis of chromosome 17q markers and breast-ovarian cancer in Icelandic families, and possible relationship to prostatic cancer. Am J Hum Genet (1993) 1.38
Progress report. Cancer of the pancreas. Gut (1977) 1.36
Cancer in survivors of childhood soft tissue sarcoma and their relatives. J Natl Cancer Inst (1987) 1.34
Pancreatic carcinoma and hereditary nonpolyposis colorectal cancer: a family study. Br J Cancer (1985) 1.34
Family studies of malignant melanoma and associated cancer. Surg Gynecol Obstet (1975) 1.34
Familial pancreatic cancer: clinicopathologic study of 18 nuclear families. Am J Gastroenterol (1990) 1.31
Peutz-Jeghers syndrome: a clinicopathologic survey of the "Harrisburg family" with a 49-year follow-up. Gastroenterology (1988) 1.26
The DCC gene product in cellular differentiation and colorectal tumorigenesis. Genes Dev (1994) 1.23
Reported family aggregation of pancreatic cancer within a population-based case-control study in the Francophone community in Montreal, Canada. Int J Pancreatol (1992) 1.21
Screening for hereditary non-polyposis colorectal cancer: a study of 22 kindreds in The Netherlands. Am J Med (1989) 1.20
Frequent loss of expression of the potential tumor suppressor gene DCC in ductal pancreatic adenocarcinoma. Cancer Res (1992) 1.18
A familial aggregation of pancreatic cancer. An in vitro study. JAMA (1982) 1.16
Familial pancreatic adenocarcinoma in three generations. A case report and a review of the literature. Cancer (1987) 1.14
Hereditary pancreatitis: three new kindreds and a critical review of the literature. Pediatrics (1973) 1.13
The Williams syndrome: evidence for possible autosomal dominant inheritance. Am J Med Genet (1993) 1.13
Expression and alternative splicing of the deleted in colorectal cancer (DCC) gene in normal and malignant tissues. Cancer Res (1994) 1.13
Systemic cancer and the FAMMM syndrome. Br J Cancer (1990) 1.12
Neoplastic diseases in families of breast cancer patients. J Med Genet (1994) 1.11
Tobacco, alcohol, and coffee and cancer of the pancreas. A population-based, case-control study in Quebec, Canada. Cancer (1991) 1.09
Epidemiology of and risk factors for pancreatic cancer. Surg Clin North Am (1995) 1.08
Cancer risk among patients with cystic fibrosis. J Pediatr (1991) 1.07
Hereditary pancreatitis. A kindred without gross aminoaciduria. Ann Intern Med (1968) 1.06
Adenocarcinoma of the pancreas in four siblings. Gastroenterology (1973) 1.05
Food habits and pancreatic cancer: a case-control study of the Francophone community in Montreal, Canada. Cancer Epidemiol Biomarkers Prev (1995) 1.04
Cancer predisposition of ataxia-telangiectasia heterozygotes. Cancer Genet Cytogenet (1990) 1.00
Frequent alterations of the tumor suppressor genes p53 and DCC in human pancreatic carcinoma. Gastroenterology (1994) 0.98
A large multisite cancer family is linked to BRCA2. J Med Genet (1995) 0.98
Are malignant melanoma patients at higher risk for a second cancer? Cancer (1991) 0.97
Pancreatic cancer and the familial atypical multiple mole melanoma (FAMMM) syndrome. Pancreas (1991) 0.96
Chronic pancreatitis and pancreatic cancer. N Engl J Med (1993) 0.96
Pancreatic adenocarcinoma in an adolescent male with Peutz-Jeghers syndrome. Hum Pathol (1986) 0.93
Familial pancreatic cancer: a family study. Pancreas (1992) 0.91
Hereditary colorectal cancer. Semin Oncol (1991) 0.91
Partial gastrectomy: a risk factor for carcinoma of the pancreas? Hum Pathol (1987) 0.90
Familial carcinoma of the pancreas. Clin Genet (1976) 0.88
Cancer of the pancreas in two brothers and one sister. Int J Pancreatol (1988) 0.86
Familial pancreatic adenocarcinoma: association with diabetes and early molecular diagnosis. J Med Genet (1995) 0.86
Variable gastrointestinal and urologic cancers in a Lynch syndrome II kindred. Dis Colon Rectum (1991) 0.83
Cancer mortality patterns among women who served in the military: the Vietnam experience. J Occup Environ Med (1995) 0.82
Proportionate mortality study of Vietnam-era veterans of Michigan. J Occup Environ Med (1995) 0.82
The significance of CD44 in human pancreatic cancer: I. High expression of CD44 in human pancreatic adenocarcinoma. Pancreas (1994) 0.82
Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med (1996) 3.07
Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet (1999) 2.36
Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. J Natl Cancer Inst (1998) 2.33
Folate-binding protein is a marker for ovarian cancer. Cancer Res (1991) 2.12
Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families. Am J Hum Genet (1998) 1.88
Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer (1997) 1.70
TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. Cancer Res (2001) 1.69
Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest (1993) 1.62
Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer (2011) 1.51
The role of genetic factors in the etiology of pancreatic adenocarcinoma: an update. Cancer Invest (2001) 1.51
Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer (2008) 1.45
Familial nontoxic multinodular thyroid goiter locus maps to chromosome 14q but does not account for familial nonmedullary thyroid cancer. Am J Hum Genet (1997) 1.42
Is there a correlation between the structure of hair and breast cancer or BRCA1/2 mutations? Phys Med Biol (2002) 1.41
Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. Semin Surg Oncol (2000) 1.40
A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet (2002) 1.35
Biallelic DICER1 mutations occur in Wilms tumours. J Pathol (2013) 1.35
Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study. J Clin Endocrinol Metab (2001) 1.35
Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators. Am J Hum Genet (1998) 1.35
Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2004) 1.34
The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer (2012) 1.34
A novel gene encoding a B-box protein within the BRCA1 region at 17q21.1. Hum Mol Genet (1994) 1.25
Extensive DNA methylation in normal colorectal mucosa in hyperplastic polyposis. Gut (2006) 1.25
Mutation analysis of the tumor suppressor PTEN and the glypican 3 (GPC3) gene in patients diagnosed with Proteus syndrome. Am J Med Genet A (2004) 1.24
Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. Pharmacogenetics (2001) 1.23
Germline truncating mutations in both MSH2 and BRCA2 in a single kindred. Br J Cancer (2004) 1.17
The contribution of founder mutations to early-onset breast cancer in French-Canadian women. Clin Genet (2009) 1.17
Allele loss and mutation screen at the Peutz-Jeghers (LKB1) locus (19p13.3) in sporadic ovarian tumours. Br J Cancer (1999) 1.16
Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer. J Clin Oncol (2000) 1.16
PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer (2012) 1.13
DICER1 hotspot mutations in non-epithelial gonadal tumours. Br J Cancer (2013) 1.13
Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis. Br J Cancer (2011) 1.11
Molecular cloning of the B-CAM cell surface glycoprotein of epithelial cancers: a novel member of the immunoglobulin superfamily. Cancer Res (1994) 1.10
A rapid fluorescent multiplexed-PCR analysis (FMPA) for founder mutations in the BRCA1 and BRCA2 genes. Clin Genet (2000) 1.07
Refinement of two chromosome 11q regions of loss of heterozygosity in ovarian cancer. Cancer Res (1996) 1.05
The influence of familial and hereditary factors on the prognosis of breast cancer. Ann Oncol (1999) 1.05
Genetic mechanisms in squamous cell carcinoma of the head and neck. Oral Oncol (2001) 1.03
An evaluation of needs of female BRCA1 and BRCA2 carriers undergoing genetic counselling. J Med Genet (2000) 1.02
Risk factors for familial and sporadic ovarian cancer among French Canadians: a case-control study. Am J Obstet Gynecol (1998) 1.01
Mutation analysis of RAD51D in non-BRCA1/2 ovarian and breast cancer families. Br J Cancer (2012) 1.00
Change in the penetrance of founder BRCA1/2 mutations? A retrospective cohort study. J Med Genet (2002) 0.98
Prevention and genetic testing for breast cancer: variations in medical decisions. Soc Sci Med (2004) 0.95
Disruption of an exon splicing enhancer in exon 3 of MLH1 is the cause of HNPCC in a Quebec family. J Med Genet (2005) 0.95
Validation study of the LAMBDA model for predicting the BRCA1 or BRCA2 mutation carrier status of North American Ashkenazi Jewish women. Clin Genet (2007) 0.94
A founder BRCA2 mutation in non-Afrikaner breast cancer patients of the Western Cape of South Africa. Clin Genet (2011) 0.94
No association between P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck. Br J Cancer (2000) 0.94
Localization of an ovarian cancer tumor suppressor gene to a 0.5-cM region between D22S284 and CYP2D, on chromosome 22q. Cancer Res (1996) 0.93
Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent. Clin Genet (2006) 0.92
LOH and mutation analysis of CDKN2 in primary human ovarian cancers. Int J Cancer (1995) 0.92
Loss of heterozygosity on chromosome 5 in sporadic ovarian carcinoma is a late event and is not associated with mutations in APC at 5q21-22. Hum Mutat (1994) 0.91
Haplotype analysis of BRCA2 8765delAG mutation carriers in French Canadian and Yemenite Jewish hereditary breast cancer families. Hum Hered (2001) 0.91
Haplotype analysis of two recurrent CDKN2A mutations in 10 melanoma families: evidence for common founders and independent mutations. Hum Mutat (1998) 0.90
Familial medullary thyroid carcinoma and prominent corneal nerves associated with the germline V804M and V778I mutations on the same allele of RET. J Med Genet (2001) 0.90
Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment. Ann Oncol (2005) 0.90
A missense mutation in both hMSH2 and APC in an Ashkenazi Jewish HNPCC kindred: implications for clinical screening. J Med Genet (1999) 0.90
Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer. J Clin Pathol (2008) 0.89
Segregation analysis of squamous cell carcinoma of the head and neck: evidence for a major gene determining risk. Ann Hum Genet (1998) 0.89
Loss of heterozygosity on chromosome 22 in ovarian carcinoma is distal to and is not accompanied by mutations in NF2 at 22q12. Br J Cancer (1994) 0.89
False family history of breast cancer in the family cancer clinic. Eur J Surg Oncol (1998) 0.89
A comprehensive analysis of MNG1, TCO1, fPTC, PTEN, TSHR, and TRKA in familial nonmedullary thyroid cancer: confirmation of linkage to TCO1. J Clin Endocrinol Metab (2001) 0.88
Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer. Br J Cancer (2003) 0.88
Triple-negative and basal-like breast cancer: implications for oncologists. Curr Oncol (2011) 0.88
BRCA1 mutations and survival in women with ovarian cancer. N Engl J Med (1997) 0.87
Constitutional alterations of the ATM gene in early onset sporadic breast cancer. J Med Genet (2002) 0.86
CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein. Int J Cancer (1997) 0.85
Is the E133K allele of VG5Q associated with Klippel-Trenaunay and other overgrowth syndromes? J Med Genet (2006) 0.85
I1307K APC and hMLH1 mutations in a non-Jewish family with hereditary non-polyposis colorectal cancer. Clin Genet (1998) 0.85
Founder BRCA1 and BRCA2 mutations in early-onset French Canadian breast cancer cases unselected for family history. Int J Cancer (2001) 0.84
Is hereditary site-specific ovarian cancer a distinct genetic condition? Am J Med Genet (1998) 0.84
Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines. Lab Invest (1996) 0.83
The polymorphic CAG repeat of the androgen receptor gene: a potential role in breast cancer in women over 40. Breast Cancer Res Treat (2001) 0.83
The importance of a family history of breast cancer in predicting the presence of a BRCA mutation. Am J Hum Genet (1999) 0.83
Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation. Clin Genet (2008) 0.83
Prevalence of founder BRCA1 and BRCA2 mutations in unselected French Canadian women with breast cancer. Clin Genet (2001) 0.83
Polymorphisms in GSTM1, GSTT1 and CYP1A1 and risk of pancreatic adenocarcinoma. Br J Cancer (2000) 0.83
Ratio of female to male offspring of women tested for BRCA1 and BRCA2 mutations. J Med Genet (2004) 0.83
Penetrance of mutations in the familial Wilms tumor gene FWT1. J Natl Cancer Inst (2000) 0.82
Genetic architecture of prostate cancer in the Ashkenazi Jewish population. Br J Cancer (2011) 0.82
The HNPCC associated MSH2*1906G-->C founder mutation probably originated between 1440 CE and 1715 CE in the Ashkenazi Jewish population. J Med Genet (2005) 0.82
BRCA1:185delAG found in the San Luis Valley probably originated in a Jewish founder. J Med Genet (2005) 0.82
Haplotype analysis of a BRCA1: 185delAG mutation in a Chilean family supports its Ashkenazi origins. Clin Genet (2002) 0.82
Family with Graves disease, multinodular goiter, nonmedullary thyroid carcinoma, and alveolar rhabdomyosarcoma. Am J Med Genet (1997) 0.82
Re: Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Natl Cancer Inst (2001) 0.81
Survival of patients with breast cancer and BRCA1 mutations. Lancet (1998) 0.81
The RNASEL 471delAAAG allele and prostate cancer in Ashkenazi Jewish men. J Med Genet (2003) 0.81
Multiple primary malignancies in a patient with situs ambiguus. Clin Genet (2006) 0.81
Loss of heterozygosity of methylenetetrahydrofolate reductase in colon carcinomas. Oncol Rep (1999) 0.81
Characterization of two Ashkenazi Jewish founder mutations in MSH6 gene causing Lynch syndrome. Clin Genet (2010) 0.80
Novel genomic insertion-- deletion in MLH1: possible mechanistic role for non-homologous end-joining DNA repair. Clin Genet (2005) 0.80
The effect of the I1307K APC polymorphism on the clinicopathological features and natural history of breast cancer. Br J Cancer (1999) 0.80
Screening mammography: the turning of the tide? Curr Oncol (2014) 0.79
Re: Magnetic resonance imaging and mammography in women with a hereditary risk of breast cancer. J Natl Cancer Inst (2001) 0.79
Transforming growth factor-beta pathway disruption and infiltration of colorectal cancers by intraepithelial lymphocytes. Histopathology (2006) 0.79
An MLH1 haplotype is over-represented on chromosomes carrying an HNPCC predisposing mutation in MLH1. J Med Genet (2002) 0.79
Genetic implications of double primary cancers of the colorectum and endometrium. J Med Genet (1998) 0.79
Preventing ovarian cancer by salpingectomy. Curr Oncol (2013) 0.78
Cutaneous malignant melanoma in women is uncommonly associated with a family history of melanoma in first-degree relatives: a case-control study. Melanoma Res (1996) 0.78
Increased risk of head and neck cancer in association with GSTT1 nullizygosity for individuals with low exposure to tobacco. Int J Cancer (2000) 0.78
Hereditary ovarian cancer resulting from a non-ovarian cancer cluster region (OCCR) BRCA2 mutation: is the OCCR useful clinically? J Med Genet (2002) 0.78
Lynch syndrome: five unanswered questions. Clin Genet (2015) 0.78